Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Mimedx Group Inc (NASDAQ: MDXG) closed at $5.26 down -2.95% from its previous closing price of $5.42. In other words, the price has decreased by -$2.95 from its previous closing price. On the day, 1.16 million shares were traded. MDXG stock price reached its highest trading level at $5.425 during the session, while it also had its lowest trading level at $5.25.
Ratios:
For a deeper understanding of Mimedx Group Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.48 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.47. For the most recent quarter (mrq), Quick Ratio is recorded 3.95 and its Current Ratio is at 4.41. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on July 02, 2024, initiated with a Overweight rating and assigned the stock a target price of $11.
On March 07, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $12.
On October 27, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $12.Craig Hallum initiated its Buy rating on October 27, 2023, with a $12 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 06 ’25 when Maersk-Moller Kimberly sold 58,300 shares for $7.42 per share. The transaction valued at 432,329 led to the insider holds 236,982 shares of the business.
Kimberly Ann Maersk-Moller bought 68,587 shares of MDXG for $502,743 on Nov 06 ’25. On May 02 ’25, another insider, Capper Joseph H, who serves as the Chief Executive Officer of the company, bought 200,000 shares for $6.34 each. As a result, the insider paid 1,268,000 and bolstered with 529,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDXG now has a Market Capitalization of 779757824 and an Enterprise Value of 655148352. As of this moment, Mimedx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.27, and their Forward P/E ratio for the next fiscal year is 22.53. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 8.35. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.98 while its Price-to-Book (P/B) ratio in mrq is 3.26. Its current Enterprise Value per Revenue stands at 1.665 whereas that against EBITDA is 9.549.
Stock Price History:
The Beta on a monthly basis for MDXG is 1.60, which has changed by -0.39609647 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, MDXG has reached a high of $9.30, while it has fallen to a 52-week low of $5.13. The 50-Day Moving Average of the stock is -20.94%, while the 200-Day Moving Average is calculated to be -22.49%.
Shares Statistics:
For the past three months, MDXG has traded an average of 985.07K shares per day and 1182020 over the past ten days. A total of 148.08M shares are outstanding, with a floating share count of 116.72M. Insiders hold about 21.19% of the company’s shares, while institutions hold 51.85% stake in the company. Shares short for MDXG as of 1767139200 were 5378136 with a Short Ratio of 5.46, compared to 1764288000 on 4444405. Therefore, it implies a Short% of Shares Outstanding of 5378136 and a Short% of Float of 4.5500003.
Earnings Estimates
The performance of Mimedx Group Inc (MDXG) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.44 and $0.4 for the fiscal current year, implying an average EPS of $0.42. EPS for the following year is $0.12, with 2.0 analysts recommending between $0.12 and $0.12.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $106.93M this quarter.It ranges from a high estimate of $111M to a low estimate of $99.5M. The current estimate, Mimedx Group Inc’s year-ago sales were $92.91MFor the next quarter, 5 analysts are estimating revenue of $86.14M. There is a high estimate of $102.5M for the next quarter, whereas the lowest estimate is $71M.
A total of 5 analysts have provided revenue estimates for MDXG’s current fiscal year. The highest revenue estimate was $411.6M, while the lowest revenue estimate was $400M, resulting in an average revenue estimate of $407.48M. In the same quarter a year ago, actual revenue was $348.88MBased on 5 analysts’ estimates, the company’s revenue will be $396.16M in the next fiscal year. The high estimate is $464.9M and the low estimate is $352.4M.
